Emcure Pharmaceuticals Ltd.
Pharma · NSE
52-week range
₹981 – ₹1,830
From 52w high
-8.3%
RSI (14)
54.7
vs SMA 50 / 200
↑ 50 · ↑ 200
Emcure Pharmaceuticals trades at ₹1,643, up 61% over the past 12 months and 5% above its 50-DMA (₹1,562), with RSI at 51.5 (neutral). The company reported Q4 FY26 net profit of ₹243.74 crore, up 24% YoY, supported by 5-year earnings CAGR of 28.8% and ROE of 19.57% — but carries a debt-to-equity ratio of 30.57, which is the most prominent structural risk in the data.
- ✓Five-year earnings CAGR of 28.8% and revenue CAGR of 16.9%, with a persistence consistency score of 98 and ROE above 15% in 4 of the last 5 years, indicate durable compounding at the operating level.
- ✓Free cash flow has been positive in 4 of 5 available years and the debt trend is classified as falling, suggesting management is actively reducing leverage from its elevated base.
- ✓At a trailing PE of 33.7 and a quality score of 54, EMCURE ranks 1st on both quality score and ROE among the 6 pharma peers in the dataset, above SUNPHARMA (quality 50), CIPLA (30), and Dr. Reddy (ROE 16.1%).
- ✓Price is 13.5% above the 200-DMA (₹1,448) with a 52-week drawdown of only 10.2%, and near-term resistance sits at ₹1,671–₹1,688, roughly 1.7–2.7% from current price.
- ✗Debt-to-equity of 30.57 is an extreme reading for the pharma sector; even with a falling trend, this level implies significant interest burden and vulnerability to rate or operating-cash-flow shocks.
- ✗A social-media controversy involving director Namita Thapar — a boycott call tied to a viral video — drew negative headlines in May 2026, and with only 8 total news items the single negative headline is disproportionately visible in recent news flow.
- ✗Analyst coverage is limited to 6 analysts, meaning the mean rating of 1.33 (1–5 scale, lower = more constructive) may shift materially on any single new initiation or downgrade.
- ✗Profit margin of 10.03% is moderate; pharma peers with stronger generic or specialty-drug pipelines may sustain higher margins if pricing pressure intensifies in key markets.
- ·Q4 FY26 net profit rose 24% YoY to ₹243.74 crore, the most recent earnings data point; the trailing-to-forward PE compression from 33.7 to 22.2 implies the market is embedding continued earnings growth into the current price.
- ·Shares briefly hit a record high in late April 2026 following reports of large block trades, and the stock is up 53% over the prior 6-month window per one news report, making it one of the stronger performers in the mid-cap pharma segment over that period.
- ·The Namita Thapar controversy (viral video, social-media boycott call) emerged in early May 2026; MD Satish Mehta was simultaneously re-appointed, providing some leadership continuity signal amid the reputational noise.
- ?At a D/E of 30.57 — even with a falling trend — what is the interest-coverage ratio, and how many years of current free-cash-flow generation would be required to reach a debt level typical of investment-grade pharma peers?
- ?The forward PE of 22.2 versus trailing PE of 33.7 implies a meaningful step-up in earnings; which specific revenue segments or geographies are expected to drive that acceleration, and how exposed are they to regulatory or pricing risk?
- ?Does the 5-year ROE persistence (4 of 5 years above 15%, consistency score 98) reflect a structural competitive advantage in the product mix, or is it amplified by the high financial leverage on the balance sheet?
- ?How material could the social-media controversy around Namita Thapar become to brand equity and prescription volumes, given Emcure's consumer-facing product categories?
PE
33.7
Forward PE
22.2
ROE
+19.6%
Profit margin
+10.0%
D/E
30.57
Dividend yield
+0.2%
Quality score
54/100
ROE 5y above 15%
4/5 yrs
FCF 5y positive
4/5 yrs
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.Analysis generated 11 May 2026.